 | | Vol. 11.48 – 8 December, 2020 |
| |
|
|
| Researchers showed that microRNA-223 (miR-223)–mediated regulation of N-glycan biosynthesis in endothelial cells (ECs) regulated endothelial-to-hematopoietic transition. MiR-223 was enriched in hemogenic endothelial cells and in oligopotent nascent hematopoietic stem and progenitor cells.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that isocitrate dehydrogenase 1-mutant mice developed myeloid dysplasia in that these animals exhibited anemia, ineffective erythropoiesis, and increased immature progenitors and erythroblasts.
[Blood] |
|
|
|
| Scientists showed that Dynole 34-2, a potent inhibitor of Dynamin GTPase activity, could block transduction of key signaling pathways and overcome chemoresistance of leukemia stem cells.
[Nature Communications] |
|
|
|
| To investigate the role of Prdm16 in adult hematopoietic stem cells, the authors generated a novel conditional knockout mouse model and deleted Prdm16 in adult mouse hematopoietic system using the IFN-inducible Mx1-Cre.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Human mRNA transcript profiling at multiple time points permited the tracking of the reprogramming of B cell nuclei to a multipotent state. Interrogation of a human B cell regulatory network with gene expression signatures identified eight candidate master regulator proteins.
[Cell Reports] |
|
|
|
| Functional studies with gene-overexpressed and gene-silenced DLBCL cell lines showed that expression of NANOG and HOXA9 promoted cell viability and inhibited apoptosis through suppression of G2 arrest in vitro and enhanced tumor formation and hepatosplenic infiltration in a tail-vein-injected mouse model.
[Scientific Reports] |
| |
|
|
| To assess the relevance of autophagy to T cell allo-immunity, the authors generated T cell specific ATG5 knock-out mice. Deficiency of ATG5 dependent autophagy reduced T cell proliferation, increased apoptosis following in vitro and in vivo allo-stimulation.
[Cancer Research] |
|
|
|
| Scientists investigated clinical features and outcomes of posttransplant relapse of acute myeloid leukemia (AML) based on data for 1265 patients with AML suffering relapse after allogeneic hematopoietic cell transplantation conducted during complete remission.
[Bone Marrow Transplantation] |
|
|
|
| Investigators performed a multicenter retrospective cohort study of patients with T-cell lymphoblastic lymphoma treated using leukemia-type initial therapies to compare the outcomes after hematopoietic stem cell transplantation at different disease stages.
[Scientific Reports] |
|
 |
|
|
|
| One of the major insights produced by such research is that diffuse large B-cell lymphoma (DLBCL) almost always stems from genetic damage that occurs during the germinal center reaction, which is required for the production of high-affinity antibodies.
[Blood Cancer Journal] |
|
|
|
| The authors summarize the manner in which hematopoietic stem cells respond to different stressors via intrinsic and extrinsic, and niche-driven mechanisms to support hematopoietic regeneration.
[Current Stem Cell Reports] |
|
|
|
|
| It is a double milestone: new evidence that cures are possible for many people born with sickle cell disease and another serious blood disorder, beta-thalassemia, and a first for the genome editor CRISPR.
[ScienceInsider] |
|
|
|
| Precision BioSciences, Inc. announced positive interim clinical results from its Phase I/IIa study of PBCAR0191, the company’s off-the-shelf allogeneic CAR T cell therapy investigational candidate targeting CD19. 27 patients including 16 patients with aggressive NHL and 11 patients with aggressive B-ALL were enrolled and evaluated.
[Precision BioSciences, Inc.] |
|
|
|
| Fate Therapeutics, Inc. announced positive interim data from the Company’s dose escalation Phase I study of FT516 in combination with rituximab for patients with relapsed/refractory B-cell lymphoma.
[Fate Therapeutics, Inc.] |
|
|
|
|
| April 14, 2021
Madison, Wisconsin, United States |
|
|
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | New York Blood Center – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
